In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback